IDH2 and acute myeloid leukemia: First-in-class, oral, selective inhibitors of mutant IDH1 (ivosidenib) [64] and IDH2 (enasidenib) [65] are FDA-approved for the management of R/R AML, based on phase 1 clinical trials showing overall response rates of 42% and 39%, respectively, along with manageable toxicity profiles.